E-Newsletter - March 2022
FY22 BIQSFP Funding Opportunity
FY22 BIQSFP Funding Opportunity | Non-Real Time (NRT) Integrated Studies
A one-time FY22 opportunity for BIQSFP supplement awards to support non-real time (NRT) integrated studies associated with randomized, phase 2 or 3 trials conducted by NCTN Groups and NCORP Research Bases i now available. NCI plans to make 3-5 supplements by September 30, 2022, and the maximum budget allowed is $500,000 in direct costs (not including subaward F&As) per supplement. These supplements will be for one year only (no outyear funding).
Given the limited number of awards that will be made, the maximum number of applications accepted will be as follows:
NCTN – Each NCTN Network Group may submit up to 3 applications.
NCORP – Each NCORP Research Base may submit up to 2 applications.
The application deadline due to NCI is June 6, 2022 and a letter of intent to be submitted to NCI by May 27, 2022. Additional details can be found in the attached announcement.
Alliance members: To allow Alliance scientific and operations leadership to select and prepare the final applications to be submitted on the behalf of the Alliance, a letter of intent, final BIQSFP checklist, and a draft budget for the project must be submitted by e-mail to Dr. Yujia Wen (Senior Director, Translational Research Operations) at ywen@bsd.uchicago.edu by May 18, 2022, 5 pm CT. Please include “FY22 NRT BIQSFP” in the e-mail subject line.
Applications forms and instructions can be downloaded from the NCI BIQSFP website: https://www.cancer.gov/about-nci/organization/ccct/funding/biqsfp. It will be greatly appreciated (though not required) if you can let Dr. Wen know your interests by e-mail as soon as possible (preferably by May 2, 2022). Final applicants for the Alliance will be notified during the week of May 23, 2022 to prepare for the final submission.
If you have any questions regarding this announcement, please contact Dr. Wen at the Alliance, Dr. Kelly Kim (240-276-7811), Ms. Beverly Lee (240-620-0561) at the NCI, or send an e-mail to NCIBIQSFP@mail.nih.gov.
For other articles in this issue of the Alliance E-News newsletter, see below.
-
Newly Implemented Changes Improve Alliance Audit Process
Scott H. Okuno, MD - Chair, Alliance Audit Committee
Kurombi Wade-Oliver, CCRP - Director, Alliance Quality Management and Audit Program -
Spotlight on Alliance Trials
A022001 (Pancreatic Endocrine Tumors)
A032001/MAIN CAV Study (Metastatic Urothelial Cancer) -
April is . . . National Cancer Control Month
Cancer in the Older Adult | Cancer Care Delivery Research
Health Disparities | Health Outcomes
Prevention | Spymtom Intervention - Alliance Foundation Funding Opportunity
- FY22 BIQSFP Funding Opportunity
-
Alliance in the News
** Molecular, Clinical, and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia
** Living with and Learning about Neuroendocrine Tumors: A Conversation with Dr. Jaydira Del Rivero
** Emerging Adjuvant Therapies in Renal Cell Carcinoma Post-ASCO GU ’22
** A Wave of New Cancer Treatments Challenges Community Oncologists to Keep up